tbuckley/cabot-search huggingface dataset:
Nomogram for predicting axillary lymph node pathological complete response after neoadjuvant chemotherapy in node-positive breast cancer patients
Authors: W. Wang, X. Wang, J. Liu, X. Wang
Journal: Annals of Oncology (2019)

Background: Pathological complete response (pCR) of axillary lymph nodes (ALNs) is frequently achieved in patients with clinically node-positive breast cancer after neoadjuvant chemotherapy (NAC), and ALN status is an important prognostic factor in breast cancer patients. Our goal is to develop a new clinical predictive model to assess the axillary lymph node pCR probability after NAC. Methods: A retrospective series of 547 patients who had biopsy-proven positive ALNs at diagnosis and undergoing axillary lymph node dissection from 2007 to 2014 in National Cancer Center/Cancer Hospital of Chinese Academy of Medical Sciences. We analyzed the clinicopathologic features and developed a nomogram to predict the probability of ALN pCR. Univariate assessment was performed using a logistic regression model. A multivariate logistic regression stepwise model was used to generate a nomogram to predict ALN pCR in node positive patients Variables with P < 0.05 on multivariable analysis were included in the nomogram. The adjusted area under the receiver operating characteristic curve (AUC) was calculated to quantify the ability to rank patients by risk. Internal validation was estimated using 70-30 hold out validation method. Nomogram was validated externally with the prospective cohort of 167 patients from 2016 to 2018. Results: In retrospective study, there were 172 (31.4%) patients achieved axillary pCR after NAC. Multivariate analysis indicated that clinical nodal (N) stage (P = 0.002), hormone receptor (HR) status (P = 0.009) and clinical response of the primary tumor after NAC (P < 0.001) were significant independent predictors for axillary pCR. The NAC nomogram was based on these three variables. In the internal validation of performance, the AUCs for the training and test sets were 0.719 and 0.753, respectively. The nomogram was validated in an external cohort with an AUC of 0.734. Conclusions: We developed a nomogram to predict the likelihood of axillary pCR in node-positive breast cancer patients after NAC. The predictive model performed well in prospective external validation. This practical tool could provide information to surgeons regarding whether to perform additional ALND after NAC. Clinical trial identification: ChiCTR1800014968. Legal entity responsible for the study: Cancer Hospital, Chinese Academy of Medical Sciences. Funding: Capital's Funds for Health Improvement and Research (2016-2-4026); CAMS Innovation Fund for Medical Sciences (2016-I2M-1-001 and 2017-I2M-3-004); National Natural Science Foundation of China (81602343); Youth Research Fund of Beijing Tiantan Hospital (2017-YQN-09). Disclosure: All authors have declared no conflicts of interest.
Author Correction: Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection
Authors: Estefania Fernandez, Wanwisa Dejnirattisai, Bin Cao, Suzanne M Scheaffer, Piyada Supasa, Wiyada Wongwiwat, Prabagaran Esakky, Andrea Drury, Juthathip Mongkolsapaya, Kelle H Moley, Indira U Mysorekar, Gavin R Screaton, Michael S Diamond
Journal: Nature Immunology (2020)
Genomic landscape of lung adenocarcinoma in East Asians
Authors: Jianbin Chen, Hechuan Yang, Audrey Su Min Teo, Lidyana Bte Amer, Faranak Ghazi Sherbaf, Chu Quan Tan, Jacob Josiah Santiago Alvarez, Bingxin Lu, Jia Qi Lim, Angela Takano, Rahul Nahar, Yin Yeng Lee, Cheryl Zi Jin Phua, Khi Pin Chua, Lisda Suteja, Pauline Jieqi Chen, Mei Mei Chang, Tina Puay Theng Koh, Boon-Hean Ong, Devanand Anantham, Anne Ann Ling Hsu, Apoorva Gogna, Chow Wei Too, Zaw Win Aung, Yi Fei Lee, Lanying Wang, Tony Kiat Hon Lim, Andreas Wilm, Poh Sum Choi, Poh Yong Ng, Chee Keong Toh, Wan-Teck Lim, Siming Ma, Bing Lim, Jin Liu, Wai Leong Tam, Anders Jacobsen Skanderup, Joe Poh Sheng Yeong, Eng-Huat Tan, Caretha L. Creasy, Daniel Shao Weng Tan, Axel M. Hillmer, Weiwei Zhai
Journal: Nature Genetics (2020)
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
Authors: Roujian Lu, Xiang Zhao, Juan Li, Peihua Niu, Bo Yang, Honglong Wu, Wenling Wang, Hao Song, Baoying Huang, Na Zhu, Yuhai Bi, Xuejun Ma, Faxian Zhan, Liang Wang, Tao Hu, Hong Zhou, Zhenhong Hu, Weimin Zhou, Li Zhao, Jing Chen, Yao Meng, Ji Wang, Yang Lin, Jianying Yuan, Zhihao Xie, Jinmin Ma, William J Liu, Dayan Wang, Wenbo Xu, Edward C Holmes, George F Gao, Guizhen Wu, Weijun Chen, Weifeng Shi, Wenjie Tan
Journal: The Lancet (2020)
12O_PR Independent Blinded Validation of the Genomic Index of Sensitivity to Endocrine Therapy (Set)
Authors: T. Karn, C. Hatzis, W.F. Symmans, L. Pusztai, E. Ruckhäberle, M. Schmidt, V. Müller, U. Holtrich, A. Rody, M. Kaufmann
Journal: Annals of Oncology (2012)
Sedation practice and discomfort during withdrawal of mechanical ventilation in critically ill patients at end-of-life: a post-hoc analysis of a multicenter study
Authors: Rene Robert, Amélie Le Gouge, Nancy Kentish-Barnes, Mélanie Adda, Juliette Audibert, François Barbier, Simon Bourcier, Jeremy Bourenne, Alexandre Boyer, Jérôme Devaquet, Guillaume Grillet, Olivier Guisset, Anne-Claire Hyacinthe, Mercé Jourdain, Nicolas Lerolle, Olivier Lesieur, Emmanuelle Mercier, Jonathan Messika, Anne Renault, Isabelle Vinatier, Elie Azoulay, Arnaud W. Thille, Jean Reignier
Journal: Intensive Care Medicine (2020)
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
Authors: Thomas A. Zelniker, Marc P. Bonaca, Remo H.M. Furtado, Ofri Mosenzon, Julia F. Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Andrzej Budaj, Robert G. Kiss, Francisco Padilla, Ingrid Gause-Nilsson, Anna Maria Langkilde, Itamar Raz, Marc S. Sabatine, Stephen D. Wiviott
Journal: Circulation (2020)

Atrial fibrillation (AF) and atrial flutter (AFL) are associated with both diabetes mellitus and its related comorbidities, including hypertension, obesity, and heart failure (HF). SGLT2 (sodium-glucose cotransporter 2) inhibitors have been shown to lower blood pressure, reduce weight, have salutary effects on left ventricular remodeling, and reduce hospitalization for HF and cardiovascular death in patients with type 2 diabetes mellitus. We therefore investigated whether SGLT2 inhibitors could also reduce the risk of AF/AFL.DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58) studied the efficacy and safety of the SGLT2 inhibitor dapagliflozin versus placebo in 17 160 patients with type 2 diabetes mellitus and either multiple risk factors for atherosclerotic cardiovascular disease (n=10 186) or known atherosclerotic cardiovascular disease (n=6974). We explored the effect of dapagliflozin on the first and total number of AF/AFL events in patients with (n=1116) and without prevalent AF/AFL using Cox and negative binomial models, respectively. AF/AFL events were identified by search of the safety database using MedDRA preferred terms ("atrial fibrillation," "atrial flutter").Dapagliflozin reduced the risk of AF/AFL events by 19% (264 versus 325 events; 7.8 versus 9.6 events per 1000 patient-years; hazard ratio [HR], 0.81 [95% CI, 0.68-0.95]; P=0.009). The reduction in AF/AFL events was consistent regardless of presence or absence of a history of AF/AFL at baseline (previous AF/AFL: HR, 0.79 [95% CI, 0.58-1.09]; no AF/AFL: HR, 0.81 [95% CI, 0.67-0.98]; P for interaction 0.89). Similarly, presence of atherosclerotic cardiovascular disease (HR, 0.83 [95% CI, 0.66-1.04]) versus multiple risk factors (HR, 0.78 [95% CI, 0.62-0.99]; P for interaction 0.72) or a history of HF (HF: HR, 0.78 [95% CI, 0.55-1.11]; No HF: HR, 0.81 [95% CI, 0.68-0.97]; P for interaction 0.88) did not modify the reduction in AF/AFL events observed with dapagliflozin. Moreover, there was no effect modification by sex, history of ischemic stroke, glycated hemoglobin A1c, body mass index, blood pressure, or estimated glomerular filtration rate (all P for interaction >0.20). Dapagliflozin also reduced the total number (first and recurrent) of AF/AFL events (337 versus 432; incidence rate ratio, 0.77 [95% CI, 0.64-0.92]; P=0.005).Dapagliflozin decreased the incidence of reported episodes of AF/AFL adverse events in high-risk patients with type 2 diabetes mellitus. This effect was consistent regardless of the patient's previous history of AF, atherosclerotic cardiovascular disease, or HF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01730534.
Open peroral endoscopic myotomy for refractory benign esophageal stricture
Authors: Chuncheng Wu, Shuanghong Luo, Linjie Guo, Bing Hu
Journal: Endoscopy (2020)

A 36-year-old woman suffered thoracic pain and dysphagia following a barbecue 6 months earlier. Gastroscopy showed an ulcer in the lower esophagus. The thoracic pain disappeared after taking proton pump inhibitors (PPIs) for a week, but dysphagia continued. Repeat gastroscopy showed a thickened and rigid lower esophageal wall and esophageal stricture ([Fig. 1 a]). The stricture was about 4.0 cm from the cardia. Endoscopic biopsy diagnosed inflammation. Esophagography showed severe stricture in the lower esophagus ([Fig. 2 a]). Thoracic computed tomography showed a thickened lower esophageal wall, and endoscopic ultrasonography showed thickening of the muscularis propria in the lower esophagus ([Fig. 3]), without manifestation of tumors. The patient continued to take PPIs and underwent three sessions of endoscopic dilation, without success; she lost 8.0 kg in weight.
Declan J Meagher
Authors: Muiris X Fitzgerald, John F Murphy
Journal: BMJ (2020)

Declan J Meagher was a most influential figure in Irish obstetrics and gynaecology during the 1960s, 70s, and 80s, making huge contributions to maternal and infant welfare.

He was born in Ferbane, County Offaly, where his father, William Meagher, was the local doctor. This was a time of great turbulence in Ireland between the war of independence and the civil war. Declan was educated initially by the local Christian Brothers and subsequently the Jesuits in Clongowes Wood College in County Kildare. He studied at University College Dublin and graduated with distinction in 1944. He decided on a career in obstetrics and gynaecology and trained initially at the National Maternity Hospital and then at the Hammersmith Hospital in London. By this time he had married Emer McMullin. Later, he was to wryly recall their impecunious postwar London days, living in very spartan, cramped accommodation; meat was a rare treat.

On his return to Dublin, now with a young family, he was appointed to the staff of the National Maternity Hospital, the hospital to which he was to devote his life’s work. In 1965 he joined the consultant staff …
Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression
Authors: Daniel Rathkey, Manakamana Khanal, Junko Murai, Jingli Zhang, Manjistha Sengupta, Qun Jiang, Betsy Morrow, Christine N. Evans, Raj Chari, Patricia Fetsch, Hye-Jung Chung, Liqiang Xi, Mark Roth, Armando Filie, Mark Raffeld, Anish Thomas, Yves Pommier, Raffit Hassan
Journal: Journal of Thoracic Oncology (2020)

BRCA1-associated protein-1 (BAP1), a nuclear deubiquitinase thought to be involved in DNA double-strand break repair, is frequently mutated in mesothelioma. Because poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPIs) induce synthetic lethality in BRCA1/2 mutant cancers, we evaluated whether BAP1 inactivating mutations confer sensitivity to PARPIs in mesothelioma and if combination therapy with temozolomide (TMZ) would be beneficial.A total of 10 patient-derived mesothelioma cell lines were generated and characterized for BAP1 mutation status, protein expression, nuclear localization, and sensitivity to the PARPIs, olaparib, and talazoparib, alone or in combination with TMZ. BAP1 deubiquitinase (DUB) activity was evaluated by ubiquitin with 7-amido-4-methylcoumarin assay. BAP1 knockout mesothelioma cell lines were generated by CRISPR-Cas9. Because Schlafen 11 (SLFN11) and O6-methylguanine-DNA methyltransferase also drive response to TMZ and PARPIs, we tested their expression and relationship with drug response.BAP1 mutations or copy-number alterations, or both were present in all 10 cell lines. Nonetheless, four cell lines exhibited intact DUB activity and two had nuclear BAP1 localization. Half maximal-inhibitory concentrations of olaparib and talazoparib ranged from 4.8 μM to greater than 50 μM and 0.039 μM to greater than 5 μM, respectively, classifying them into sensitive (two) or resistant (seven) cells, independent of their BAP1 status. Cell lines with BAP1 knockout resulted in the loss of BAP1 DUB activity but did not increase sensitivity to talazoparib. Response to PARPI tended to be associated with high SLFN11 expression, and combination with temozolomide increased sensitivity of cells with low or no MGMT expression.BAP1 status does not determine sensitivity to PARPIs in patient-derived mesothelioma cell lines. Combination of PARPI with TMZ may be beneficial for patients whose tumors have high SLFN11 and low or no MGMT expression.
Practical Guide to Meta-analysis
Authors: Shipra Arya, Todd A. Schwartz, Amir A. Ghaferi
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial
Authors: David Corcoran, Aleksandra Radjenovic, Ify R Mordi, Sheraz A Nazir, Simon J Wilson, Markus Hinder, Denise P Yates, Surendra Machineni, Jose Alcantara, Margaret F Prescott, Barbara Gugliotta, Yinuo Pang, Niko Tzemos, Scott I Semple, David E Newby, Gerry P McCann, Iain Squire, Colin Berry
Journal: Cardiovascular Research (2020)

Abstract Aims The effects of serelaxin, a recombinant form of human relaxin-2 peptide, on vascular function in the coronary microvascular and systemic macrovascular circulation remain largely unknown. This mechanistic, clinical study assessed the effects of serelaxin on myocardial perfusion, aortic stiffness, and safety in patients with stable coronary artery disease (CAD). Methods and results In this multicentre, double-blind, parallel-group, placebo-controlled study, 58 patients were randomized 1:1 to 48 h intravenous infusion of serelaxin (30 µg/kg/day) or matching placebo. The primary endpoints were change from baseline to 47 h post-initiation of the infusion in global myocardial perfusion reserve (MPR) assessed using adenosine stress perfusion cardiac magnetic resonance imaging, and applanation tonometry-derived augmentation index (AIx). Secondary endpoints were: change from baseline in AIx and pulse wave velocity, assessed at 47 h, Day 30, and Day 180; aortic distensibility at 47 h; pharmacokinetics and safety. Exploratory endpoints were the effect on cardiorenal biomarkers [N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hsTnT), endothelin-1, and cystatin C]. Of 58 patients, 51 were included in the primary analysis (serelaxin, n = 25; placebo, n = 26). After 2 and 6 h of serelaxin infusion, mean placebo-corrected blood pressure reductions of −9.6 mmHg (P = 0.01) and −13.5 mmHg (P = 0.0003) for systolic blood pressure and −5.2 mmHg (P = 0.02) and −8.4 mmHg (P = 0.001) for diastolic blood pressure occurred. There were no between-group differences from baseline to 47 h in global MPR (−0.24 vs. −0.13, P = 0.44) or AIx (3.49% vs. 0.04%, P = 0.21) with serelaxin compared with placebo. Endothelin-1 and cystatin C levels decreased from baseline in the serelaxin group, and there were no clinically relevant changes observed with serelaxin for NT-proBNP or hsTnT. Similar numbers of serious adverse events were observed in both groups (serelaxin, n = 5; placebo, n = 7) to 180-day follow-up. Conclusion In patients with stable CAD, 48 h intravenous serelaxin reduced blood pressure but did not alter myocardial perfusion.
Asthma in urban and rural pre‐ and primary schoolchildren according to the latest GINA definition
Authors: Pedro T. B. S. Branco, Maria C. M. Alvim‐Ferraz, Fernando G. Martins, Catarina Ferraz, Luísa G. Vaz, Sofia I. V. Sousa
Journal: Allergy (2020)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Infographic. Exercise for intermittent claudication
Authors: Garry A Tew, Louise Allen, Christopher D Askew, Ian Chetter, Gabriel Cucato, Patrick Doherty, Andrew Garnham, Amy Harwood, Lee Ingle, Michael Jenkins, Jonathan Michaels, Sara Pittack, Chris Seenan, Hazel Trender
Journal: British Journal of Sports Medicine (2020)

Intermittent claudication (IC) is pain or discomfort in the muscles of the calf, thigh or buttock that occurs during walking and is relieved by rest. It affects 4% of people over 60 years of age and is the most common symptom of peripheral arterial disease (PAD). For people with IC, the goals of treatment are twofold: (1) secondary prevention of cardiovascular disease through management of risk factors (eg, tobacco use, dyslipidaemia, diabetes, hypertension and physical inactivity); (2) improving functional status, with treatment options including exercise training, revascularisation and vasodilator therapy.1

In 2012, the UK’s National Institute for Health and Care Excellence published a clinical guideline on the diagnosis and …
ヒトXPD遺伝子を導入後のトリコチオジストロフィー(裂毛症)細胞における,正常なDNA修復活性と変異の発現 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Marionnet C, Quilliet X, Benoit A, Armier J, Sarasin A, Stary A
Journal: Cancer Research (1996)
Magnesium and vitamin C supplementation attenuates steroid-associated osteonecrosis in a rat model
Authors: Li-Zhen Zheng, Jia-Li Wang, Jian-Kun Xu, Xiao-Tian Zhang, Bao-Yi Liu, Le Huang, Ri Zhang, Hai-Yue Zu, Xuan He, Jie Mi, Qian-Qian Pang, Xin-Luan Wang, Ye-Chun Ruan, De-Wei Zhao, Ling Qin
Journal: Biomaterials (2020)
The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer
Authors: Wu Sun, Jialu Li, Likun Zhou, Jiayi Han, Rui Liu, Haiyang Zhang, Tao Ning, Zhiying Gao, Baorui Liu, Xi Chen, Yi Ba
Journal: Theranostics (2020)

Oxaliplatin (OXA) resistance is the major obstacle to the anticancer effects of chemotherapy in colorectal cancer (CRC) patients. MicroRNAs (miRNAs) play an important role in the chemoresistance of various tumors. Our objective is to clarify the underlying mechanism of miRNAs in chemoresistance and provide a potential strategy to improve the response of CRC patients to chemotherapeutics. Methods: MiRNA microarray and Real-time PCR were performed to compare changes in miRNA expression between oxaliplatin-resistant and the parental cells. CCK8, apoptosis assay, immunofluorescence and xenograft studies were used to elucidate the impact of miR-27b-3p on regulating chemoresistance. Luciferase reporter assay and western blot were carried to assess the regulatory role of miR-27b-3p in ATG10 expression. The effects of miR-27b-3p and ATG10 on autophagy were investigated by GFP-LC3 fluorescence microscopy, transmission electron microscopy, and western blot. ChIP assay and luciferase assay were performed to test the c-Myc's occupancy on the miR-27B promoter. Results: We observed that miR-27b-3p expression was significantly downregulated in oxaliplatin-resistant cell lines (SW480-OxR and HCT116-OxR) compared to the corresponding parental cell lines and that miR-27b-3p expression was positively correlated with disease-free survival (DFS) time in colorectal cancer patients. MiR-27b-3p could sensitize colorectal cancer cells to oxaliplatin in vitro and in vivo. Under oxaliplatin treatment, chemoresistant cells showed a higher autophagy level than parental cells. Moreover, we also identified that miR-27b-3p inhibited the expression of ATG10 at the posttranscriptional level, thus inhibiting autophagy. Further study demonstrated that c-Myc can inhibit the expression of miR-27b-3p via binding to the promoter region of miR-27B gene. Conclusions: Our study identifies a novel c-Myc/miR-27b-3p/ATG10 signaling pathway that regulates colorectal cancer chemoresistance. These results suggest that miR-27b-3p is not only a potential indicator for evaluating efficiency of chemotherapy, but also a valuable therapeutic target for CRC, especially for patients with chemoresistance.
Home-Based Physical Therapy for Older Adults After Hip Fracture
Authors: Zhijie Xu, Jianjiang Pan, Yi Qian
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Catathrenia resolved with the lowest CPAP pressure settings
Authors: Teresa Gómez, Ana Casal, María del Pilar Carballosa De Miguel, Paula Rodríguez Rodríguez, María Fernanda Troncoso Acevedo, Farah Ezzine De Blas
Journal: Pulmonology (2020)

Abstract   Catathrenia is a sleep disorder characterized by a prolonged expiratory sound preceded by a deep inhalation and accompanied by a bradypnea breathing-pattern. Afflicted individuals are usually unaware of their problem, so it is common that bed partners report strange sounds while breathing during sleep. There is little documented experience in treating the condition, but some studies have shown resolution of this disorder with CPAP, especially in patients with a Sleep-Disordered-Breathing (SDB) associated. Usually high-pressure-levels are recommended. We describe a patient with a self-limited benign condition (without SDB associated), with clinical repercussions due to sleep fragmentation, responding favorably to a low setting on CPAP (4 cmH20). We believe a low setting CPAP-treatment can improve nocturnal groaning episodes and daytime complaints increasing adherence.